Project Grant R16AI192297
Award Date 9/20/25
Completion Date 8/31/29
Dollars Obligated $750K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Mississippi, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $742,499 Project Grant to the University of Alabama at Birmingham (UAB) for the "Molecular Investigation of Siderophore Secretion and Drug Efflux by Mycobacterium Tuberculosis" research project. This 5-year project, running from August 2025 to July 2030, aims to shed light on the unique siderophore secretion system in Mycobacterium...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $224,943 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Massachusetts to conduct research on "Cell Wall Carbohydrate Recycling in Mycobacterium tuberculosis". The research aims to identify and characterize a novel mechanism for recycling the peptidoglycan component of the Mycobacteriales cell wall, which may promote survival of non-replicating...
- This federal Project Grant award, totaling $404,108, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to identify the key genetic and signaling pathways that enable Mycobacterium tuberculosis (MTB) to form antibiotic persister cells, which can survive prolonged exposure to lethal antibiotics. The research aims to apply genetic and proteomic approaches to...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,248,740 Project Grant through the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to Michigan State University on July 7, 2025. The grant supports the development of a new series of nitrofuran compounds that are potent inhibitors against Mycobacterium tuberculosis (MTB) and Mycobacterium abscessus (MAB), the bacteria that cause tuberculosis and non-tuberculous mycobacterial infections,...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $301,826 Project Grant on August 20, 2025 to the University of Washington to develop novel agents to eliminate tuberculosis (TB) persisters. The grant, under CFDA 93.855 - Allergy and Infectious Diseases Research, aims to assess the potential of the FDA-approved drug netupitant (NTP) as an anti-persister agent for TB treatment. The University of Washington will use molecular genetic and biochemical strategies to define...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,922,220 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Johns Hopkins University. The grant supports research to advance apoptosis-inducing agents as host-directed therapy for tuberculosis (TB). The research aims to boost host immune responses via the intrinsic apoptosis pathway to reduce Mycobacterium tuberculosis (MTB) growth and enhance the bactericidal activity of...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $429,546 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to National Jewish Health in Colorado. The grant will fund research to evaluate the efficacy of tuberculosis (TB) treatment regimens by analyzing the transcriptomic patterns of Mycobacterium tuberculosis injury and adaptation during drug treatment. The research aims to develop more reliable preclinical measures of TB treatment...
- This $193,375 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify bacterial determinants that may contribute to variable treatment responses for tuberculosis (TB). The project, conducted by researchers at the Harvard T.H. Chan School of Public Health, aims to investigate the effects of clinically prevalent variants in the ESX1 secretion system on TB...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $298,829 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Tarn Biosciences, Inc. to develop novel nitroreductase-activated inhibitor compounds as treatments for tuberculosis (TB) and nontuberculous mycobacterial (NTM) infections. The funding, awarded on August 21, 2025, supports the discovery and preclinical development of a lead candidate compound, HC2210, which has shown...
- The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,166,933 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Vanderbilt University Medical Center to study Mycobacterium tuberculosis transmission. The project aims to identify bacterial genetic and phenotypic features associated with M. tuberculosis transmission outcomes, including infection, subclinical TB, and clinical TB disease. It will also define M. tuberculosis...